Dengue vaccines at a crossroad

See allHide authors and affiliations

Science  06 Nov 2015:
Vol. 350, Issue 6261, pp. 626-627
DOI: 10.1126/science.aab4047

You are currently viewing the summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution


The era when most vaccines provided efficacy well beyond 90% is over. Many of the more recently developed vaccines only provide partial efficacy. Although vaccines are typically licensed on the basis of demonstrated efficacy, the ultimate goal of vaccination goes far beyond efficacy. In addition to averting disease and death at an individual level, vaccination programs should decrease the public health burden of diseases at the population level. What counts is the impact on the reduction of vaccine-preventable disease incidence through direct and indirect protection, which is particularly pertinent for diseases that are of high public health importance.